Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Overzicht Blincyto® (blinatumomab) informatie
BLINCYTO® (blinatumomab)
For healthcare professionals managing B-cell precursor acute lymphoblastic leukaemia (B-ALL), this page offers streamlined access to approved Australian indications for BLINCYTO® (blinatumomab), including PBS eligibility. Explore clinical data, safety insights, and resources for evidence-based care.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.